Λεπτομέρειες βιβλιογραφικής εγγραφής
| Τίτλος: |
Dassault Systèmes to Buy Drug Trial Software Firm ArisGlobal. |
| Συγγραφείς: |
Berthelot, Benoit (AUTHOR) |
| Πηγή: |
Bloomberg.com. 7/23/2026, pN.PAG-N.PAG. 1p. |
| Θεματικοί όροι: |
*Mergers & acquisitions, *Artificial intelligence, *Private equity, *Computer software industry, *Business software, Life sciences, Medical software |
| Εταιρία/Οντότητα: |
Dassault Systèmes SA |
| Περίληψη: |
The article focuses on Dassault Systèmes SE's acquisition of ArisGlobal, a drug trial software maker, for up to $2 billion as part of its expansion into life sciences. Dassault will purchase ArisGlobal from Nordic Capital, a Swedish private equity firm, with $1.8 billion in cash and $200 million in additional payouts. The acquisition comes amid challenges for Dassault, including a 26% share price decline this year and concerns over AI disrupting its core software business. ArisGlobal employs artificial intelligence to assist life science companies in drug development, regulation, and safety monitoring, aligning with Dassault’s commitment to advancing its life sciences division despite recent revenue declines. [Extracted from the article] |
|
Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Βάση Δεδομένων: |
Business Source Index |